Cost-effectiveness of intensive adjuvant chemotherapy for high-risk breast cancer: Is tailored and dose-escalated chemotherapy with growth factor support (GFS) more costly and less effective than marrow-supported high-dose chemotherapy - Results from a randomized study

Acta Oncologica

Volumn 46, Issue 2, 2007, Pages 146-152

  Kellokumpu Lehtinen, P ^a   Bergh, J ^b   Salminen, E ^d   Wiklund, T ^c   Lehtinen, S ^e   Aronen, P ^f   Sintonen, H ^f  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b KAROLINSKA INSTITUTE   (Sweden)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d TURKU UNIVERSITY HOSPITAL   (Finland)

^e TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^f UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAMOXIFEN; THIOTEPA;

ADULT; ARTICLE; BONE MARROW SUPPRESSION; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; FEMALE; FOLLOW UP; HEALTH CARE COST; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

ADULT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COST-BENEFIT ANALYSIS; FEMALE; FILGRASTIM; FINLAND; HUMANS; MIDDLE AGED; PROSPECTIVE STUDIES; RISK; SURVIVAL;

EID: 33847034480     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860600965012     Document Type: Article

References (38)

1. Bergh J, Wiklund T, Erikstein B, Lidbrink E, Lindman H, Malmstrom P, et al. Marrow supported high dose therapy is not superior compared with tailored FEC in the adjuvant setting to high risk breast cancer. Results of a randomized study. Lancet 2000;356:1384-91.
2. Chang S, Long SR, Kutikova L, Bowman L, Finley D, Crown WH, et al. Estimating the cost of cancer: Results on basis of claims data analyses for cancer patients diagnosed with seven types of cancer during 1999-2000. J Clin Oncol 2004;22:3524-30.
3. Radice D, Redaelli A. Breast cancer management. Quality of life and cost considerations. Pharmacoenonomics 2003;21:383-96.
4. Dunscombe P, Samant R, Roberts G. A cost-outcome analysis of adjuvant postmastectomy locoregional radiotherapy in high-risk postmenopausal breast cancer patients. Int J Radiat Oncol Biol Phys 2000;48:977-82.
5. Brown RE, Hutton J, Burrell A. Cost effectiveness of treatment options in advanced breast cancer in the UK. Pharmacoeconomics 2001;19:1091-102.
6. Higa GM. Aromatase inhibitors for breast cancer: Pharmacoeconomic considerations. Expert Opin Pharmacother 2001;2:987-95.
7. Pagano E, Ponti A, Gelormino E, Merletti F, Mano MP. An economic evaluation of the optimal workload in treating surgical patients in a breast unit. Eur J Cancer 2003;39:748-54.
8. Verma S, Ilersich AL. Population-based pharmacoeconomic model for adopting capecitabine/docetaxel combination treatment for anthracycline- pretreated metastatic breast cancer. Oncologist 2003;8:232-40.
9. Mello MM, Brennan TA. The controversy over high-dose chemotherapy with autologous bone marrow transplant for breast cancer. Health Aff (Millwood) 2001;20:101-17.
10. Schulman KA, Stadtmauer EA, Reed SD, Glick HA, Goldstein LJ, Pines JM, et al. Economic analysis of conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoetic stem-cell transplantation for metastatic breast cancer. Bone Marrow Trans 2003;31:205-10.
11. Rodenhuis S, Richel D, van der Wall E, Schornagel JH, Baars JW, Koning CC, et al. Randomised trial of high-dose chemotherapy and haematopoetic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement. Lancet 2003;352:515-21.
12. Rodenhius S, Bontenbal M, Beex LV, Wagstaff J, Ricehl DJ, Nooij MA, et al. High dose chemotherapy with hematopoietic rescue for high risk breast cancer. New Eng J Med 2003;349:7-16.
13. Hortobagyi GN, Buzdar AU, Theriault RL, Valero V, Frey D, Booser DJ, et al. Randomised trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast cancer. J Natl Cancer Inst 2000;92:225-33.
14. Tallman MS, Gray R, Robert NJ, LeMaistre CF, Osborne CK, Vaughan WP, et al. Conventional adjuvant chemotherapy with or without high dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Eng J Med 2003;349:17-26.
15. Elfenbein GJ. Stem cell transplantation for high risk-breast cancer. N Eng J Med 2003;349:80-2.
16. Wheatley K, Gray RG, Ives NJ. Correspondence. High dose chemotherapy for breast cancer. N Eng J Med 2003;349:1476-7.
17. Bergh J, Wiklund T, Erikstein B, Fornander T, Bengtsson N-O, Malmström P, et al. Dosage of adjuvant G-CSF (Filgrastim) supported FEC polychemotherapy based on equivalent hematological toxicity to high risk breast cancer. Ann Oncol 1998;9:1-9.
18. Ithaka R, Gentleman R. A language for data analysis and graphics. J Comput Graph Stat 1996;5:299-314.
19. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomized trials. Lancet 2005;365:1665-717.
20. Bergh J. Where next with stem-cell-supported high-dose therapy for breast cancer? Lancet 2000;355:944-5.
21. Champlin RE. Peripheral blood progenitor cells: A replacement for marrow transplantation? Semin Oncol 1996;23:15-21.
22. Brice P, Gordin S, Libert O, Marolleau JP, Makki J, Extra JM, et al. Influence of the granulocyte growth factor on the cost of bone marrow autografts in oncologic hematology. Presse Medicale 1994;23:1512-5.
23. Overgaard M. Radiotherapy as part of multidisciplinary treatment strategy in early breast cancer. Eur J Cancer 2001;37:33-43.
24. Faulkner LB, Tucci F, Tamburini A, Tintori V, Lippi AA, Bambi F, et al. G. G-CSF serum pharmacokinetics during peripheral blood progenitor cell mobilization: Neutrophil count-adjusted dosage might potentially improve mobilization and be more cost-effective. Bone Marrow Trans 1998;21:1091-5.
25. Kath R, Hartmann M, Hoffken K. Pharmacoeconomic evaluation of high-dose chemotherapy and peripheral blood stem cell support in high-risk or poor-prognosis malignancies. J Cancer Res Clin Oncol 1998;124:288-90.
26. Bensinger W, Appelbaum F, Rowley S, Storb R, Sanders J, Lilleby K, et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 1995;13:2547-55.
27. Frey P, Stinson T, Siston A, Knight SJ, Ferdman E, Traynor A, et al. Lack of caregivers limits use of outpatient hematopoetic stem cell transplant program. Bone Marrow Trans 2002;30:741-8.
28. Bredeson C, Malcolm J, Davis M, Bence-Bruckler I, Kearns B, Huebsch L. Cost analysis of the introduction of PBPC for autologous transplantation: Effect of switching from bone marrow (BM) to peripheral blood progenitor cells (PBPC). Bone Marrow Trans 1997;20:889-96.
29. Meisenberg BR, Ferran K, Hollenbach K, Brehm T, Jollon J, Piro LD. Reduced charges and costs associated with outpatient autologous stem cell transplantation. Bone Marrow Trans 1998;21:927-32.
30. Meisenberg BR, Miller WE, McMillan R, Callgahn M, Sloan C, Brehm T, et al. Outpatient high-dose chemotherapy with autologous stem cell rescue for hematologic and nonhematologic malignancies. J Clin Oncol 1997;15:11-7.
31. Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradisher WJ, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of intergroup trial C9741/Cancer and Leukemia Group B trial 9741. J Clin Oncol 2003;21:14311-439.
32. Peters WP, Rosner GL, Vredenburgh JJ, Shpall EJ, Crump M, Richardson PG, et al. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: A report of CALGB 9082, SWOG 9114, and NCIC MA-13. J Clin Oncol 2005;23:2191-200.
33. Beltz SE, Yee GC. Pharmacoeconomics of cancer therapy. Cancer Control 1998;5:415-24.
34. Chirikos TN, Ruckdeschel JC, Krischer JP. Economic analysis of cancer treatment costs: Another tool for oncology managers. J Oncol Manag 2001;10:11-7.
35. Koopmanschap MA, Touw KC, Rutter FF. Analysis of costs and cost-effectiveness in multinational trials. Health Policy 2001;58:175-86.
36. Ridenour TA, Treloar JH, Dean RS. Utility analysis for clinical decision-making in small treatments settings. Int J Neuroscience 2003;113:417-30.
37. Wilking N, Jönsson B. A pan-European comparison of regarding patient access to cancer drugs. Stockholm, Sweden: Karolinska Institute; 2005.
38. Kievit W, Bolter MJ, van der Wilt GJ, Bult P, Thunissen FB, Meijer J, et al. Cost-effectiveness of new guidelines for adjuvant systemic therapy for breast cancer. Ann Oncol 2005;16:1874-81.